January | February | March | April | May | June | July | August | September | October |
| ||||||
| Deal title | Principal company | Partner company | Amount awarded ($M) | Date |
| CEPI to award funding to develop Afrigen's mRNA vaccine against Rift Valley fever | Afrigen Biologics Pty Ltd. | Coalition for Epidemic Preparedness Innovations | $6.20 | 1/20/25 |
| DARPA to award Arzeda funding for its AI platform for rapid and strong design of proteins | Arzeda Corp. | Defense Advanced Research Projects Agency | Payment unspecified | 1/23/25 |
| Scaleready awarded funding to Brainchild to support the development and commercial of BCB-276 against diffuse intrinsic pontine glioma | Brainchild Bio Inc. | Scaleready LLC | $0.30 | 1/21/25 |
| OEP to invest in Cambium Oncology to advance the clinical development of ANT-308 for acute myeloid leukemia | Cambium Oncology LLC | Orient Europharma Co. Ltd. | $5.00 | 1/13/25 |
| NIH to award Cambium Oncology funding to support the clinical development of ANT-308 for acute myeloid leukemia | Cambium Oncology LLC | National Institutes of Health | $2.40 | 1/13/25 |
| CARB-X to award Clarametyx funding to advance the development of CMTX-301 into lead optimization, to prepare for preclinical (IND-enabling) and phase 1 evaluation against bacterial infections | Clarametyx Biosciences Inc. | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $2.60 | 1/7/25 |
| KIAT to award funding to develop Evotec's tRNA synthetases against lung diseases | Evotec SE | Korea Institute for Advancement of Technology | $4.50 | 1/22/25 |
| CIRM to award Fate Therapeutics funding to support IND-enabling activities for FT-836 | Fate Therapeutics Inc | California Institute of Regenerative Medicine | Payment unspecified | 1/31/25 |
| LifeArc to award Glox funding to develop precision antibiotics against cystic fibrosis | Glox Therapeutics Ltd. | Lifearc Pvt. Ltd. | $0.64 | 1/21/25 |
| Michael J. Fox Foundation to award Grifols' funding to identify plasma-based biomarkers and to develop diagnostic tools and new disease-modifying therapeutics for Parkinson's disease | Grifols SA | The Michael J Fox Foundation for Parkinson's Research | $21.00 | 1/14/25 |
| CARB-X to award Immunartes funding to develop a monoclonal antibody against Staphylococcus aureus infections | Immunartes LLC | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $0.73 | 1/23/25 |
| NIA to award Jupiter Neurosciences funding to evaluate Jotrol against Alzheimer’s disease | Jupiter Neurosciences Inc. | National Institute on Aging | Payment unspecified | 1/13/25 |
| NIH to award KI funding for the research project against autism | Karolinska Institutet | National Institutes of Health | $2.50 | 1/21/25 |
| ERC to award KI funding to develop vaccines adapted to genetic variations against multiple indications | Karolinska Institutet | European Research Council | $0.16 | 1/23/25 |
| Promobilia foundation to award Karolinska Institutet funding to support development of a treatment for inherited retinal diseases | Karolinska Institutet | Promobilia Foundation | $0.93 | 1/31/25 |
| Bill & Melinda Gates Foundation to award Micron Biomedical funding to develop measles-rubella vaccine | Micron Biomedical Inc. | Bill & Melinda Gates Foundation | $7.50 | 1/7/25 |
| CEPI to award funding to study Micron’s microarray technology to deliver vaccine against COVID-19 | Micron Biomedical Inc. | Coalition for Epidemic Preparedness Innovations | $3.70 | 1/8/25 |
| BARDA to award Micron Biomedical funding to develop mRNA-based broad protecting flu vaccine | Micron Biomedical Inc. | Biomedical Advanced Research and Development Authority | $2.00 | 1/13/25 |
| BARDA to award Moderna funding of $590M to develop mRNA-based avian-variant vaccines; HHS terminated the grant on May 28 | Moderna Inc. | Biomedical Advanced Research and Development Authority | Payment unspecified | 1/17/25 |
| NIH to award Ocean Biomedical funding to identify vaccine targets against malaria | Ocean Biomedical Inc. | National Institutes of Health | Payment unspecified | 1/29/25 |
| BARDA to award Partner Therapeutics funding for a phase II study of Leukine in sepsis patients | Partner Therapeutics Inc. | Biomedical Advanced Research and Development Authority | Payment unspecified | 1/9/25 |
| CARB-X to award Peptilogics funding to develop zaloganan-CR to prevent fracture related infections | Peptilogics Inc. | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $3.30 | 1/9/25 |
| Osteosarcoma Institute to award Peptomyc funding for the phase II clinical study of OMO-103 in patients with advanced osteosarcoma | Peptomyc SL | The Osteosarcoma Institute | Payment unspecified | 1/16/25 |
| CARB-X to award Rhode Island Hospital funding to study proof-of-concept of PCR approach feasibility of direct from blood detection of bacterial pneumonia | Rhode Island Hospital | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $1.00 | 1/28/25 |
| Scaleready to award Seattle Children's Research Institute funding for CAR-T platform development | Seattle Children’s Research Institute | Scaleready LLC | $0.12 | 1/8/25 |
| CIRM to award Senti Biosciences funding to develop SENTI-202 program | Senti Biosciences Inc. | California Institute for Regenerative Medicines | $1.50 | 1/1/25 |
| BARDA to award funding to develop Shionogi's S-892216 against COVID-19 infection | Shionogi and Co. Ltd. | Biomedical Advanced Research and Development Authority | $375.00 | 1/16/25 |
| CIRM to award UCLA funding to develop a hematopoietic stem cell gene therapy (HSC-GT) against Angelman syndrome | University of California Los Angeles | Foundation for Angelman Syndrome Therapeutics UK | $5.80 | 1/30/25 |
| CARB-X to award JLU a grant to support the development of ADC-56 targeting Gram-negative pathogens | University of Giessen | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $0.61 | 1/16/25 |
| NIH to award Vast Therapeutics funding to develop ALX-1 for cystic fibrosis and other chronic lung infections | Vast Therapeutics Inc. | National Institutes of Health | $2.00 | 1/21/25 |
| Scaleready to award Vaxcell-Bio a G-Rex Grant to support the development of VYPC-1 and Vax-CAR-MIL therapy against cancer | Vaxcell-Bio Co. Ltd. | Scaleready LLC | $0.21 | 1/8/25 |
| BARDA to award Vaxxas funding to advance commercialization of microneedle patch-based mRNA vaccines | Vaxxas Pty. Ltd. | Biomedical Advanced Research and Development Authority | $2.00 | 1/15/25 |
| CEPI to award Vaxxas funding to develop heat-stable, dried-formulation mRNA vaccines, including GBP-56 delivered using needle-free high-density microarray patch | Vaxxas Pty. Ltd. | Coalition for Epidemic Preparedness Innovations | $4.80 | 1/22/25 |
| IFLI to award an investment to Verismo to advance the development of SynKIR-310 pipeline for follicular lymphoma and other non-Hodgkin lymphoma subtypes | Verismo Therapeutics Inc. | Institute for Follicular Lymphoma Innovation | $4.05 | 1/7/25 |
| Innosuisse to award Ymmunobio funding to develop Radio-pharmaceutical YB-800 for solid tumors | Ymmunobio AG | Innosuisse Management AG | Payment unspecified | 1/23/25 |
| European Innovation Council to award Alzecure funding to conduct a phase II clinical study of ACD-856 for Alzheimer's disease and pain | Alzecure Pharma AB | European Commission | $2.67 | 2/17/25 |
| NHMRC to award Biosceptre funding to develop monoclonal antibodies | Biosceptre International Ltd. | National Health and Medical Research Council | Payment unspecified | 2/1/25 |
| Department of Defense to award Cedars-Sinai funding to advance the development of ENV-205 against chemotherapy drug resistance and cachexia | Cedars-Sinai Medical Center | US Department of Defense | $0.60 | 2/18/25 |
| DeGregorio Family Foundation to award Columbia University funding to support the development of TFF2-MSA for gastroesophageal cancer treatment | Columbia University Irving Medical Center | DeGregorio Family Foundation | $0.12 | 2/6/25 |
| March of Dimes to award Columbia University Irving Medical Center funding to immune-related proteins for spontaneous preterm birth | Columbia University Irving Medical Center | March of Dimes (US) | $0.20 | 2/18/25 |
| CIRM to award funding to develop CRD's antisense oligonucleotide therapy against SCA3 | Cure Rare Disease Inc. | California Institute of Regenerative Medicine | $5.69 | 2/6/25 |
| NIAID to award Dare? Bioscience funding to support non-clinical activities to support the development of DARE-HPV | Dare Bioscience Inc. | National Institute of Allergy and Infectious Diseases | Payment unspecified | 2/6/25 |
| CIRM to award funding to develop Entos' ENTLEP-001 against congenital generalized lipodystrophy | Entos Pharmaceuticals Inc. | California Institute of Regenerative Medicine | $4.00 | 2/5/25 |
| CEPI to award Ethris funding to support proof-of-concept research to develop spray-dried RNA vaccines | Ethris GmbH | Coalition for Epidemic Preparedness Innovations | $5.00 | 2/11/25 |
| Innosuisse to award Haya Therapeutics funding to develop lncRNA against solid tumors | Haya Therapeutics SA | Innosuisse Management AG | $1.71 | 2/12/25 |
| LCRF and ICRF to award Hebrew University of Jerusalem funding to support IGF2BP1 against Colorectal Carcinomas | Hebrew University of Jerusalem | Lung Cancer Research Foundation | $0.18 | 2/18/25 |
| CARB-X to award Immunethep funding to develop a conjugated peptide-based vaccine against infectious diseases including Escherichia coli | Immunethep SA | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $2.00 | 2/25/25 |
| Pace to award Infex funding to develop BamA inhibitor for MDR resistant Gram negative bacterial infections | Infex Therapeutics Ltd. | Pathways to Antimicrobial Clinical Ef?cacy | $1.28 | 2/17/25 |
| Erling-Persson Foundation to award KI funding to develop therapy against Parkinson’s disease | Karolinska Institutet | Familjen Erling-Perssons Stiftelse | $0.74 | 2/19/25 |
| MJFF to award Kazia Therapeutics funding to evaluate paxalisib for the treatment of Parkinson's disease | Kazia Therapeutics Ltd. | The Michael J Fox Foundation for Parkinson's Research | Payment unspecified | 2/20/25 |
| NIAID to award Lactiga funding to advance LCTG-001 against immune deficiency | Lactiga Inc. | National Institute of Allergy and Infectious Diseases | Payment unspecified | 2/3/25 |
| European Innovation Council to award Nanophoria funding to develop NP-MP1 for heart failure | Nanophoria Srl | European Commission | $18.67 | 2/26/25 |
| NEA to award Nationwide Children's Hospital funding to develop staphylococcus aureus vaccine for atopic dermatitis | Nationwide Children's Hospital | National Eczema Association | Payment unspecified | 2/27/25 |
| CIRM to award Navega funding to support the preclinical development of NT-Z001 for chronic neuropathic pain | Navega Therapeutics Inc. | California Institute of Regenerative Medicine | $4.00 | 2/4/25 |
| NCCN to award Northwestern University funding to support a phase I study of futibatinib for gastroesophageal cancer | Northwestern University | National Comprehensive Cancer Network Inc. | Payment unspecified | 2/25/25 |
| Ramsay Hospital Research Foundation to award Redhill Biopharma funding for phase II study of opaganib in combination with darolutamide for metastatic castrate-resistant prostate cancer | Redhill Biopharma Ltd. | Ramsay Health Care Ltd. | Payment unspecified | 2/4/25 |
| Medical Research Agency to award Ryvu Therapeutics funding to develop antibody drug conjugates | Ryvu Therapeutics SA | Agencja Bada? Medycznych | $2.48 | 2/17/25 |
| Eurostars to award Teitur funding to develop peptide therapeutics for hearing loss | Teitur Trophics ApS | Eurostars | $2.13 | 2/5/25 |
| CPRIT to award University of Texas MD Anderson funding for cancer research | The University of Texas MD Anderson Cancer Center | Cancer Prevention and Research Institute of Texas | $23.00 | 2/19/25 |
| NIH to award TGen funding to conduct a preclinical study of SIWA-318 to target and eliminate senescent cells in pancreatic ductal adenocarcinoma | Translational Genomics Research Institute | National Institutes of Health | $0.49 | 2/11/25 |
| NCCN to award University Hospitals Seidman Cancer Center funding to support a phase II study of Trifluridine plus oxaliplatin in biliary tract cancer | University Hospitals Seidman Cancer Center | National Comprehensive Cancer Network Inc. | Payment unspecified | 2/25/25 |
| Wellcome to award University of Bath funding to study cognitive decline and premature brain ageing in psychotic disorders, including schizophrenia | University of Bath | Wellcome Ltd. | $4.48 | 2/17/25 |
| French government to award Allogenica funding to develop XL-001 for leukemia and lymphoma | Allogenica SAS | French Government | $2.67 | 3/19/25 |
| NHMRC to award AIBN funding to develop next-generation nanoparticles against triple-negative breast cancer | Australian Institute for Bioengineering and Nanotechnology | National Health and Medical Research Council | $3.00 | 3/24/25 |
| NIDA to award Benuvia funding for the GMP synthesis of psilocybin and other bulk drug substances | Benuvia Operations LLC | National Institute on Drug Abuse | Payment unspecified | 3/25/25 |
| LRA to award Western Reserve University funding to develop BAFF-CAR NK cell therapies for lupus | Case Western Reserve University School of Medicine | Lupus Research Alliance | $0.30 | 3/20/25 |
| NIIMBL to award Landmark Bio funding to support the development of recombinant AAV gene therapy vectors for rare diseases | Chromatan Inc. | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 3/17/25 |
| MJFF to award Endlyz funding to develop small molecule potentiators against PD | Endlyz Therapeutics Inc | The Michael J Fox Foundation for Parkinson's Research | $2.20 | 3/31/25 |
| French Health Innovation Agency to award Institut Pasteur funding to conduct phase Ia clinical study of Mopevac for Lassa fever | Institut Pasteur | Ministere De La Defense Service De Sante Des Armees | Payment unspecified | 3/31/25 |
| LRA to award King's College London funding to develop CAR T cell therapy against lupus | King's College London | Lupus Research Alliance | Payment unspecified | 3/20/25 |
| NIAID to award Lactiga STTR funding to develop sIgA nasal immunotherapies for immunodeficient conditions | Lactiga US Inc. | National Institute of Allergy and Infectious Diseases | Payment unspecified | 3/10/25 |
| European Commission to award Leniobio funding to develop Alice cell-free protein production platform | Leniobio GmbH | European Commission | Payment unspecified | 3/13/25 |
| ARPA-H to award Luminary Therapeutics funding to develop a mesothelin CAR T therapy against non-small cell lung cancer and colorectal cancer | Luminary Therapeutics | The Advanced Research Projects Agency for Health | $5.80 | 3/11/25 |
| GHIT to award MMV funding to develop therapeutics against Chikungunya virus infection | Medicines for Malaria Venture | Global Health Innovative Technology Fund | $0.16 | 3/18/25 |
| National Multiple Sclerosis Society to award Myrobalan Therapeutics funding to support the preclinical and translational development of MRO-002 against multiple sclerosis | Myrobalan Therapeutics Inc. | National Multiple Sclerosis Society | $0.85 | 3/13/25 |
| Japan Agency for Medical Research and Development to award Optieum's funding to develop OPTF-01 for glioblastoma | Optieum Biotechnologies Inc. | Japan Agency for Medical Research and Development | $39.00 | 3/18/25 |
| NIH to award PCRC funding to conduct a preclinical study on RMC-7977 in combination with daraxonrasib for RAS mutated pancreatic cancer | Penn Pancreatic Cancer Research Center | National Institutes of Health | Payment unspecified | 3/19/25 |
| LRA to award Perelman School of Medicine funding to develop CAR T cell therapy targeting ABCs to protect from infections | Perelman School of Medicine at the University of Pennsylvania | Lupus Research Alliance | Payment unspecified | 3/20/25 |
| AMED to award RegCell funding to support the development of epigenetic reprogramming platform for autoimmune diseases | Regcell Inc. | Japan Agency for Medical Research and Development | $37.30 | 3/18/25 |
| GHIT Fund to award Shionogi funding to conduct research and identify new T. cruzi active series for Chagas disease | Shionogi & Co. Ltd. | Global Health Innovative Technology Fund | $0.15 | 3/17/25 |
| MCDC to award funding to develop Tonix's TNX-801 against mpox and smallpox | Tonix Pharmaceuticals Holding Corp. | Medical CBRN Defense Consortium | Payment unspecified | 3/10/25 |
| GHIT to award funding to develop VLP's vaccine against dengue virus infection | VLP Therapeutics LLC | Global Health Innovative Technology Fund | $5.90 | 3/18/25 |
| CGLFF to award WashU Medicine funding to develop therapies against Alzheimer's disease | Washington University in St Louis School of Medicine | Carol and Gene Ludwig Family Foundation | $4.50 | 3/7/25 |
| French government to award funding to develop 4MB's 4P-004 against osteoarthritis | 4Moving Biotech SAS | French Government | $7.99 | 4/8/25 |
| The Michael J. Fox Foundation for Parkinson’s Research to award Accure Therapeutics funding for the preclinical activities of ACT-02 for Parkinson’s disease | Accure Therapeutics SL | The Michael J. Fox Foundation for Parkinson’s Research | $1.12 | 4/13/25 |
| Australian Government to award Advancell funding to perform the first-in-field clinical platform trial of 212Pb-ADVC-001 against metastatic prostate cancer | Advancell Pty Ltd. | Australian Government | $18.00 | 4/13/25 |
| MRFF to award Advancell funding to develop and deliver targeted therapies against prostate cancer | Advancell Pty Ltd. | Medical Research Future Fund | $18.00 | 4/23/25 |
| CARB-X to award Arrepath funding to advance antibiotic to treat multidrug-resistant infections | Arrepath Inc. | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $3.70 | 4/3/25 |
| Advancium to award Asha Therapeutics funding to conduct a preclinical study of ASHA-624 for ADOA | Asha Therapeutics LLC | Advancium Health Network | Payment unspecified | 4/23/25 |
| Cancer Drugs Fund to award Astrazeneca to support the treatment of capivasertib in combination with fulvestrant for (HR)-positive HER2-negative breast cancer | Astrazeneca plc | Cancer Research UK | Payment unspecified | 4/11/25 |
| US DOD to award Cedars-Sinai funding to conduct phase I clinical study of ENV-105 in combination with Osimertinib and to identify related biomarkers against non-small cell lung cancer | Cedars-Sinai Medical Center | US Department of Defense | $0.88 | 4/17/25 |
| Undisclosed foundation to award Cingulate funding to support the development of CTx-2103 against anxiety | Cingulate Inc. | Undisclosed | $6.50 | 4/9/25 |
| CZ Biohub to award CUVCPS funding to develop chimeric autoantibody receptor T-cells therapy against autoimmune diseases | Columbia University Roy and Diana Vagelos College of Physicians and Surgeons | Chan Zuckerberg Biohub Inc. | Payment unspecified | 4/3/25 |
| NIH to award Exozymes funding for Bioclick project to enhance and accelerate the engineering of enzymes using AI for advanced chemical reactions | Exozymes Inc. | National Institutes of Health | $0.30 | 4/10/25 |
| ARPA-H to award a contract to Ginkgo Bioworks to develop a manufacturing process to produce biologic and small molecule API's | Ginkgo Bioworks Holdings Inc. | The Advanced Research Projects Agency for Health | $29.00 | 4/10/25 |
| PACE to award Immunethep funding to support the development of bGAPDH targeted monoclonal antibodies for Escherichia coli and Klebsiella pneumoniae infections | Immunethep SA | Pathways to Antimicrobial Clinical Ef?cacy | $1.26 | 4/2/25 |
| Ministry of Health and Welfare to award funding to develop Inthera's INT-101 against norovirus infection | Inthera Inc | Ministry of Health and Welfare of Korea | Payment unspecified | 4/17/25 |
| LJI to award Kyowa Kirin funding to conduct research on cell and gene therapies for various diseases | Kyowa Kirin Co. Ltd. | La Jolla Institute for Immunology | Payment unspecified | 4/3/25 |
| EU to award Lifearc funding to advance the development of repurposing medicines for rare diseases | Lifearc Pvt. Ltd. | The European Union | Payment unspecified | 4/15/25 |
| Scaleready to award March Biosciences funding to manufacture MB-105 for CD5 positive T-cell lymphomas | March Biosciences Inc. | Scaleready LLC | $0.20 | 4/29/25 |
| Spark NS to award Michigan State University funding to develop a gene therapy against Parkinson’s disease | Michigan State University | Spark NS Inc. | $2.00 | 4/3/25 |
| NIDA to award Myosin Therapeutics funding to initiate phase I clinical trial to assess the safety, tolerability, and pharmacokinetics of MT-110 against MUD | Myosin Therapeutics Inc. | National Institute on Drug Abuse | $3.00 | 4/28/25 |
| Spark NS to award Feinberg School of Medicine funding to develop a calcium channel inhibitor against Parkinson’s Disease | Northwestern University Feinberg School of Medicine | Spark NS Inc. | $2.00 | 4/3/25 |
| NIH to award Revive Therapeutics funding to evaluate Bucillamine in cancer patients | Revive Therapeutics Ltd. | National Institutes of Health | Payment unspecified | 4/9/25 |
| CZ Biohub to award Rockefeller University funding to develop chemical proteomic platforms for selective targeting of immune proteins with small molecules | Rockefeller University | Chan Zuckerberg Biohub Inc. | Payment unspecified | 4/3/25 |
| Spark NS to award UCLA funding to develop a small molecule therapeutic against Parkinson’s disease | University of California Los Angeles | Spark NS Inc. | $2.00 | 4/3/25 |
| LifeArc to award USAMRIID funding to develop a therapeutic against Crimean-Congo hemorrhagic fever virus | US Army Medical Research Institute of Infectious Diseases | Lifearc Pvt. Ltd. | Payment unspecified | 4/22/25 |
| CEPI to award Vitrivax funding to develop ALTA technology to deliver multi-dose regimens into a single, controlled-release vaccination against infectious diseases | Vitrivax Inc. | Coalition for Epidemic Preparedness Innovations | $5.00 | 4/24/25 |
| Spark NS to award Weill Cornell Medicine funding to develop a bioenergetic activator against Parkinson’s disease | Weill Cornell Medicine | Spark NS Inc. | $2.00 | 4/3/25 |
| Chan Zuckerberg Biohub to award Yale University funding to study the variations in T-cell receptors against infections and cancer | Yale University | Chan Zuckerberg Biohub Inc. | Payment unspecified | 4/3/25 |
| Scaleready to award A2 Biotherapeutics funding to support the development, system qualification and G-CART process against cancers | A2 Biotherapeutics | Scaleready LLC | $0.30 | 5/6/25 |
| CEPI to award ACM Biolabs funding to conduct a preclinical proof of concept studies on mRNA delivery technology using Rabies as a model pathogen | ACM Biolabs Pte. Ltd. | Coalition for Epidemic Preparedness Innovations | $2.87 | 5/8/25 |
| U.S. Department of Defense to award Armata funding to support phase IIa clinical study of AP-SA02 for complicated Staphylococcus aureus bacteremia infection | Armata Pharmaceuticals Inc. | U.S. Department of Defense | $4.65 | 5/1/25 |
| U.S. Government to award Bavarian Nordic contract options for production and supply of freeze-dried smallpox/mpox vaccines | Bavarian Nordic A/S | Biomedical Advanced Research and Development Authority | $143.60 | 5/6/25 |
| CPRIT to award Biodexa Pharmaceuticals funding to conduct the phase III, registrational study of eRapa in familial adenomatous polyposis | Biodexa Pharmaceuticals plc | Cancer Prevention and Research Institute of Texas | $3.00 | 5/22/25 |
| Bio-Techne to award CHLA funding to support the development of CAR-T cell therapies | Children's Hospital Los Angeles | Bio-Techne Corp. | $0.30 | 5/14/25 |
| Massventures to award Eascra Biotech START funding to support the development of JBNps to improve hard-to-treat conditions | Eascra Biotech | Massventures | $0.10 | 5/19/25 |
| French Government to award Eligo funding to develop CRISPR-based topical therapeutics using topical gene delivery platform for acne vulgaris | Eligo Bioscience SA | French Government | $5.00 | 5/13/25 |
| MJFF to award VIB-VUB funding to develop nanobodies to restore GCase function in Parkinson’s disease | Flanders Institute for Biotechnology VZW | The Michael J Fox Foundation for Parkinson's Research | Payment unspecified | 5/27/25 |
| Farmer Family Foundation to award Hillhurst Biopharmaceuticals funding to advance the phase IIa clinical development against Parkinson's disease | Hillhurst Biopharmaceuticals Inc. | Farmer Family Foundation | $4.30 | 5/8/25 |
| MJFF to award Hillhurst Biopharmaceuticals funding to advance the phase IIa clinical development against Parkinson's disease | Hillhurst Biopharmaceuticals Inc. | The Michael J Fox Foundation for Parkinson's Research | $2.00 | 5/8/25 |
| CEPI to award IVI funding to develop materials for vaccine trials against severe fever with thrombocytopenia syndrome | International Vaccine Institute | Coalition for Epidemic Preparedness Innovations | Payment unspecified | 5/15/25 |
| Crafoord Foundation to award KI funding to develop an autoantibody against RA | Karolinska Institutet | The Crafoord Foundation | Payment unspecified | 5/9/25 |
| Michael J. Fox Foundation to award KI funding to study golexanolone against Parkinson's disease in mouse model | Karolinska Institutet | The Michael J Fox Foundation for Parkinson's Research | Payment unspecified | 5/22/25 |
| DeGregorio Family Foundation to award Massachusetts General Hospital funding to advance immunotherapy for gastroesophageal cancer | Massachusetts General Hospital | DeGregorio Family Foundation | $0.22 | 5/6/25 |
| Brain Cancer Canada to award funding to McGill University to develop gene therapy treatment for PHGG | McGill University | Brain Cancer Canada | $0.10 | 5/12/25 |
| NRC IRAP to award ME Therapeutics funding to develop mRNA therapeutic candidates for cancer and inflammatory disease | Me Therapeutics Inc. | National Research Council of Canada | $0.14 | 5/21/25 |
| NIH to award funding for Nuravax' Duvax to support phase I clinical trial for Alzheimer's disease | Nuravax Inc. | National Institutes of Health | $3.00 | 5/5/25 |
| INSERM to award OSE funding to support HexARN program to develop LNP-mRNA therapies for inflammatory disorders and autoimmune diseases | OSE Immunotherapeutics SA | Institut National De La Sante Et De La Recherche Medicale | $1.37 | 5/21/25 |
| NINDS to award Quiver funding for development of platform to predict safety of central nervous system-targeted antisense oligonucleotide therapeutics | Quiver Bioscience Inc. | National Institute of Neurological Disorders and Stroke | $2.15 | 5/20/25 |
| CIRM to award Senti Biosciences additional funding to develop SENTI-202 program | Senti Biosciences Inc. | California Institute for Regenerative Medicines | $1.00 | 5/22/25 |
| CPRIT to award MD Anderson Cancer Center funding for cancer research | The University of Texas MD Anderson Cancer Center | Cancer Prevention and Research Institute of Texas | $5.49 | 5/21/25 |
| EIB to award Treefog Therapeutics loan to support cell therapy program for Parkinson’s disease | Treefrog Therapeutics SAS | European Investment Bank | $31.55 | 5/27/25 |
| The Michael J. Fox Foundation to award Umercrine Cognition funding to support preclinical study of Golexanolone for Parkinson’s-related sleep dysfunction and cognitive impairments | Umecrine Cognition AB | The Michael J Fox Foundation for Parkinson's Research | $0.42 | 5/5/25 |
| Brain Cancer Canada to award funding to University of Toronto to identify microRNAs for the development of therapeutics against Glioblastoma | University of Toronto | Brain Cancer Canada | $0.08 | 5/5/25 |
| Bio-Techne to award Norris CCCIR funding to support the development of phase I/II CAR-T cell therapy for metastatic solid cancers | USC Norris Comprehensive Cancer Center | Bio-Techne Corp. | $0.27 | 5/14/25 |
| EU to award VHIO funding to conduct Pragmatil clinical study of TIL-ACT for cancer | Vall d'Hebron Institut d'Oncologia | EU Horizon 2020 | Payment unspecified | 5/20/25 |
| Alzheimer’s Research UK to award The Alborada Drug Discovery Institute funding to develop next generation of treatments for dementia | Alborada Drug Discovery Institute | Alzheimer's Research UK | Payment unspecified | 6/24/25 |
| NIH to award Astrocyte Pharmaceuticals funding to develop AST-004 against concussion | Astrocyte Pharmaceuticals Inc. | National Institutes of Health | $3.00 | 6/17/25 |
| AMED to award Avencell Japan funding to advance the development of AVC-203 for B-cell lymphomas | Avencell Therapeutics Inc. | Japan Agency for Medical Research and Development | $40.00 | 6/30/25 |
| NIDA to award Dimerx funding to advance the development of DMX-101 as a non-addictive oral therapy for chronic lower back pain | Dimerx Inc. | National Institute on Drug Abuse | $15.00 | 6/25/25 |
| Gates Foundation to award Evaxion funding to explore design options for a polio vaccine | Evaxion Biotech AS | Bill & Melinda Gates Foundation Trust | Payment unspecified | 6/3/25 |
| Bpifrance to award Everzom funding for exosome bioproduction platform to develop drug candidates | Everzom SAS | Bpifrance | $3.16 | 6/17/25 |
| Chiesi Global Rare Diseases to award University of Exeter funding to conduct research on FAB- PAIN project to explore biomarkers in Fabry disease | Exeter University | Chiesi Global Rare Diseases plc | Payment unspecified | 6/23/25 |
| Scaleready to award G-Rex Immuneel Therapeutics funding to support the manufacture of CAR-T cell therapies | Immuneel Therapeutics Pvt. Ltd. | Scaleready LLC | $0.15 | 6/10/25 |
| National Cancer Institute to award Jabez Biosciences funding to conduct phase I clinical trial for JBZ-001 against acute myeloid leukemia | Jabez Biosciences Inc. | National Cancer Institute | $3.40 | 6/23/25 |
| Novartis Canada to award McGill funding to support the research of JAK inhibitor for the treatment of steroid refractory and immune-related adverse events secondary to immune checkpoint inhibitors | McGill University | Novartis Pharmaceuticals Canada Inc. | Payment unspecified | 6/1/25 |
| NIDA to award Mount Sinai funding to conduct a study on drug overdoses and opioid overdoses | Mount Sinai Health System Inc. | National Institute on Drug Abuse | Payment unspecified | 6/10/25 |
| NIAD to award Mink funding to support the development of allo-iNKT cell therapy to prevent and treat graft-versus-host disease in hematopoietic stem cell transplantation | National Institute of Allergy and Infectious Diseases | Mink Therapeutics | Payment unspecified | 6/2/25 |
| Retinal Degeneration Fund to award Opus Genetics funding to develop preclinical development of OPGx-MERTK Program for retinitis pigmentosa | Opus Genetics Inc. | Retinal Degeneration Fund | $2.00 | 6/23/25 |
| Chiesi Global Rare Diseases to award Ospedale Pediatrico Bambino funding to develop an in vitro system and to discovery therapeutic options in cystinosis | Ospedale Pediatrico Bambino Gesu | Chiesi Global Rare Diseases Plc | Payment unspecified | 6/23/25 |
| Gates Foundation to award Precisio Biotix funding to discover engineered lysins against bacterial vaginosis | Precisio Biotix Therapeutics Inc. | Bill & Melinda Gates Foundation Trust | Payment unspecified | 6/16/25 |
| MRFF to award Pimera funding for PMR-116 to conduct phase Ia/b study against multiple cancers | Primera Therapeutics Inc. | Medical Research Future Fund | Payment unspecified | 6/18/25 |
| Bpifrance to award Priothera funding to support the MOCART clinical study of mocravimod against rare blood cancer | Priothera Ltd. | Bpifrance EPIC | $1.79 | 6/24/25 |
| Japan AMED to award Rakutan's funding to develop RM-0256 for malignant epithelial tumors | Rakuten Medical Inc. | Japan Agency for Medical Research and Development | Payment unspecified | 6/4/25 |
| Gitlab Foundation to award Restoringvision funding for therapies against presbyopia | Restoringvision | Gitlab Inc. | $0.63 | 6/10/25 |
| Solve to award Simmaron Research funding to accelerate the study of Rapamycin for myalgic encephalomyelitis/chronic fatigue syndrome, long Covid, and other infection-associated chronic conditions and illnesses | Simmaron Research Inc. | Solve ME | Payment unspecified | 6/17/25 |
| Novartis Canada to award University of British Columbia funding to conduct phase II clinical study of 177Lu-PSMA-617 compared to cabazitaxel in patients with metastatic castration-resistant prostate cancer | University of British Columbia | Novartis Pharmaceuticals Canada Inc. | Payment unspecified | 6/10/25 |
| WEDC to award UP Oncolytics funding to advance oncolytic virus therapy for brain cancer | UP Oncolytics Inc. | Wisconsin Economic Development Corp. | $0.07 | 6/25/25 |
| CEPI to award Abera Bioscience funding to advance the immune-boosting bacterial platform for nasal vaccines | Abera Bioscience AB | Coalition for Epidemic Preparedness Innovations | $0.49 | 7/22/2025 |
| NIAAA to grant Biosymetrics to support the development of a AI platform to accelerate drug discovery for alcohol use disorder | Biosymetrics Inc. | National Institute on Alcohol Abuse and Alcoholism | $1.85 | 7/23/2025 |
| CARB-X to award Centauri Therapeutics funding to develop ABX-01 for Gram negative bacterium infection | Centauri Therapeutics Ltd. | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $5.10 | 7/29/2025 |
| Heart Foundation to award Centenary Institute catalyst partnership grant to develop drug therapy against Alzheimer’s disease | Centenary Institute Cancer Medicine & Cell Biology | National Heart Foundation of Australia | Payment unspecified | 7/3/2025 |
| Gates Foundation to award Codagenix and PATH funding to develop stabilized oral polio vaccine candidates | Codagenix Inc. | Gates Foundation | Payment unspecified | 7/22/2025 |
| NIA to award Cognition funding to conduct phase II START clinical study of CT-1812 in patients with early Alzheimer’s disease | Cognition Therapeutics Inc. | National Institute on Aging | $80.00 | 7/1/2025 |
| MJFF to award Congruence funding to develop GCase activators and correctors for Parkinson’s disease in patients with GBA1 mutations | Congruence Therapeutics Inc. | The Michael J Fox Foundation for Parkinson's Research | $5.00 | 7/24/2025 |
| CLL Society to award Dana Farber Cancer Institute funding to evaluate glofitamab combination therapies against RT in CLL | Dana Farber Cancer Institute Inc | CLL Society Inc. | Payment unspecified | 7/21/2025 |
| Government of Wallonia to award Genflow Biosciences funding to develop GF-1002 for metabolic associated steatohepatitis | Genflow Biosciences plc | Walloon Region of Belgium Government | $4.54 | 7/17/2025 |
| Scaleready to award G-Rex grant to develop HG-CT-1 against acute myeloid leukemia | Hemogenyx Pharmaceuticals plc | Scaleready LLC | $0.12 | 7/16/2025 |
| Gates Foundation to award ICRC funding to conduct phase III trial of MK-8527 against HIV-1 infection | International Clinical Research Center | Gates Foundation Trust | Payment unspecified | 7/14/2025 |
| NCCN to award UCLA funding to assess zipalertinib against non-small cell lung cancer | Jonsson Comprehensive Cancer Center | National Comprehensive Cancer Network Inc. | Payment unspecified | 7/9/2025 |
| CARB-X to award Kinvard Bio funding to develop oxepanoprolinamide program against lower respiratory tract infections and skin and soft tissue infections | Kinvard Bio Inc. | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $2.70 | 7/29/2025 |
| DTIF to award LIfT funding to advance IMAN therapy for treatment resistance in solid tumors | LIfT Biosciences Ltd. | Disruptive Technologies Innovation Fund | $13.61 | 7/29/2025 |
| FSR to award MUV funding to identify metabolic targets for therapeutic intervention against sarcoidosis | Medical University of Vienna | Foundation for Sarcoidosis Research | $0.15 | 7/14/2025 |
| EC to award Minoryx funding for the development of leriglitazone to treat lethal orphan CNS diseases | Minoryx Therapeutics SL | European Commission | $2.95 | 7/17/2025 |
| EIC to award Oncomatryx funding to develop and to support phase I trial of OMTX-705 for pancreatic, colorectal, and lung cancer | Oncomatryx SL | European Commission | $14.18 | 7/15/2025 |
| NPC to award Ostia funding to conduct clinical trials for probiotics against oral health issues | Ostia Sciences Inc | Natural Products Canada | $0.35 | 7/18/2025 |
| CEPI to award POP BIO funding to conduct research on SNAP protein vaccine platform | POP Biotechnologies Inc. | Coalition for Epidemic Preparedness Innovations | $1.50 | 7/24/2025 |
| CF Foundation to award Prime Medicine funding to advance the development of CFTR gene therapy against cystic fibrosis | Prime Medicine Inc. | Cystic Fibrosis Foundation | $6.00 | 7/16/2025 |
| NIH to award Syntis funding to advance SYNT platform and drug programs against obesity and homocystinuria | Syntis Bio Inc. | National Institutes of Health | $5.00 | 7/1/2025 |
| SCCC to award Sylvester Innovates Fund for UMMSM to support the discovery of therapeutics, diagnostics, digital health and other interventions against cancer | University of Miami Miller School of Medicine | University of Miami Sylvester Comprehensive Cancer Center | $1.00 | 7/11/2025 |
| Scaleready to award G-Rex grant to University of Minnesota to develop therapies against epithelial ovarian cancer, solid tumors and Batten disease | University of Minnesota | Scaleready LLC | $0.66 | 7/31/2025 |
| NIH to award SBIR funding to support IND-enabling studies and to prepare for first-in-human clinical trials of Virtici's VTC-880 against periodontitis | Virtici LLC | National Institutes of Health | Payment unspecified | 7/2/2025 |
| Rare Bird Foundation to award Weill Cornell Medicine funding to develop therapies against MCHS | Weill Cornell Medicine | Rare Bird Foundation | $1.10 | 7/23/2025 |
| Simons Foundation to award Allos Pharma funding to support the clinical development of arbaclofen for autism spectrum disorder | Allos Pharma Inc. | Simons Foundation | Payment unspecified | 8/21/2025 |
| CzechInvest to award CasInvent funding to develop ten drug candidates against melanoma | CasInvent Pharma AS | CzechInvest Technological Incubation Program | $0.21 | 8/25/2025 |
| NCATS to award Cila Therapeutics funding to advance the development of CIL-Key platform | Cila Therapeutics Inc. | National Center For Advancing Translational Sciences | Payment unspecified | 8/14/2025 |
| IFLI to award CIT Therapeutics investment to support clinical development of SB-4826 against non-Hodgkin Lymphoma | CIT Therapeutics Inc. | Institute for Follicular Lymphoma Innovation | $2.50 | 8/13/2025 |
| Commonwealth of Virginia to award CivicaRx funding to develop and produce insulin for diabetes | Civica Inc. | DMAS Commonwealth of Virginia | $3.00 | 8/7/2025 |
| NIDDK to award Phase II SBIR Emmyon funding to support the development of therapeutics for obesity and T2D | Emmyon Inc. | National Institute of Diabetes and Digestive and Kidney Diseases | Payment unspecified | 8/2/2025 |
| NCI to award Phase I SBIR Endure Biotherapeutics funding to support the development of ENB against FAP | Endure Biotherapeutics Inc. | National Cancer Institute | Payment unspecified | 8/12/2025 |
| Scaleready to award Gates Institute G-Rex grant to develop CAR T-cell manufacturing platform | Gates Institute | ScaleReady LLC | $0.30 | 8/14/2025 |
| NIA to award Lighthouse Pharmaceuticals funding to advance phase II clinical trial of LHP-588 in P. gingivalis-positive Alzheimer's disease patients | Lighthouse Pharmaceuticals Inc. | National Institute on Aging | $49.20 | 8/22/2025 |
| MJFF to award Lysoway funding to support the preclinical development of TRPML1 agonist against Parkinson’s Disease | Lysoway Therapeutics Inc. | The Michael J Fox Foundation for Parkinson's Research | $2.93 | 8/6/2025 |
| NCI to award Myosin Therapeutics funding to initiate a phase I trial of MT-125 against glioblastoma | Myosin Therapeutics Inc | National Cancer Institute | $4.50 | 8/19/2025 |
| EU to award Nanocell funding to develop non-viral in vivo CAR-T therapies against cancer and autoimmune diseases | Nanocell Therapeutics Inc. | The European Union | Payment unspecified | 8/14/2025 |
| NIH to award Neonc STTR grant to support the clinical development and preclinical study of NEO-212 for cancer | Neonc Technologies Inc. | National Institutes of Health | $2.50 | 8/7/2025 |
| BARDA to award Osivax funding to develop OVX-836 against influenza | Osivax SAS | Biomedical Advanced Research and Development Authority | 19.5 | 8/26/2025 |
| Government of Navarra to award Palobiofarma to develop dual A2A/H3 receptor antagonist against Parkinson’s disease | Palobiofarma SL | Government of Navarra | Payment unspecified | 8/28/2025 |
| CARB-X to award funding to evaluate Phiogen's PHI-BI-01 against ExPEC bloodstream infections | Phiogen Inc. | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator | $1.10 | 8/26/2025 |
| Scaleready to award Sidra Medicine funding to support the development of G-Rex centric CAR-T cell production platform for CAR-T cell therapy manufacturing against pediatric cancer | Sidra Medical & Research Center | Scaleready LLC | $0.10 | 8/5/2025 |
| VLAIO to award Spica Therapeutics funding to advance the development of anti-CD163 depleting monoclonal antibody against cancer and infectious diseases | Spica Therapeutics NV | Flanders Innovation & Entrepreneurship | $1.13 | 8/27/2025 |
| CEPI to award Sumitomo funding to develop DSP-0546LP for COVID-19 vaccine | Sumitomo Pharma Co. Ltd. | Coalition for Epidemic Preparedness Innovations | Payment unspecified | 8/1/2025 |
| NIH to award Trethera an SBIR grant to develop TRE-515 combined with radiation therapy against mCRPC | Trethera Corp. | National Institutes of Health | $2.30 | 8/26/2025 |
| NCC to award Vaxcellbio funding for the development of dual-target CAR-T immunotherapy into clinical studies against solid tumor | Vaxcell-Bio Co. Ltd. | National Cancer Center Inc. | $2.10 | 8/25/2025 |
| NIAID to award Weill Cornell Medicine funding to study HIV reservoir cells, develop immunotherapies and neutralizing antibodies against HIV | Weill Cornell Medicine | National Institute of Allergy and Infectious Diseases | $14.90 | 8/15/2025 |
| NIH to award funding to develop Advantage's AD-04 against Alzheimers disease | Advantage Therapeutics Inc. | National Institutes of Health | $2.50 | 9/26/2025 |
| Institut Curie to award Alligator Bioscience funding to initiate a phase II/III clinical trial of mitazalimab in combination with FOLFOX chemotherapy against biliary tract cancer | Alligator Bioscience AB | Institut Curie | Payment unspecified | 9/8/2025 |
| NIH to award UG3/UH3 grant to develop atai's 5-HT2A/2C receptor agonists for OUD | Atai Life Sciences NV | National Institutes of Health | $11.40 | 9/18/2025 |
| Gates Foundation to award Auravax Therapeutics funding to develop NanoSTING-001 against influenza A and B | Auravax Therapeutics Inc. | Gates Foundation | Payment unspecified | 9/15/2025 |
| ScaleReady to award Cedars Sinai Biomanufacturing Center funding to support the preclinical development of CAR-T cell therapy against pancreatic adenocarcinoma | Cedars Sinai Biomanufacturing Center | Scaleready LLC | $0.30 | 9/9/2025 |
| Cureator to award Cincera Therapeutics preclinical funding to develop small molecule drugs against fibrotic diseases | Cincera Therapeutics Pty Ltd. | Cureator | $0.13 | 9/4/2025 |
| NCI to award funding to conduct phase Ib study of Dogwood Therapeutics' SP-16 for cancer related pain, including chemotherapy induced neuropathy | Dogwood Therapeutics Inc. | National Cancer Institute | Payment unspecified | 9/29/2025 |
| MQ to award Feldan funding to develop mRNA-based therapies against undisclosed indication | Feldan Therapeutics Inc. | Medicament Quebec | $1.08 | 9/23/2025 |
| Cureator to award Frontier Inflammasome Therapeutics preclinical funding to develop small molecule drugs against inflammatory conditions of the lungs and skin | Frontier Inflammasome Therapeutics Pty Ltd. | Cureator | $0.17 | 9/4/2025 |
| NEI to award Phase II SBIR funding to iVeena to advance the development of IVMED-85 for pediatric myopia | iveena Delivery Systems Inc. | National Eye Institute | $2.00 | 9/18/2025 |
| NIH to award FDA grant to support clinical trial of Jaguar Health's Canalevia-CA1 for CID in dogs | Jaguar Health Inc | National Institutes of Health | $0.25 | 9/25/2025 |
| European Union to award Karolinska Institutet funding to evaluate the safety and efficacy of antiretroviral regimens in HIV patients | Karolinska Institutet | The European Union | Payment unspecified | 9/10/2025 |
| CEPI to award funding to develop KM Biologics' LC16m8 against mpox virus infection | KM Biologics Co Ltd | Coalition for Epidemic Preparedness Innovations | $10.40 | 9/11/2025 |
| NIAAA to award Küleon Bioscience funding to advance KB-128 for the treatment of alcohol-use disorder | Küleon LLC | National Institute on Alcohol Abuse and Alcoholism | $2.00 | 9/23/2025 |
| NIDDK to award Lactiga funding to develop sIgA antibody for inflammatory bowel disease | Lactiga US Inc. | National Institute of Diabetes and Digestive and Kidney Diseases | Payment unspecified | 9/4/2025 |
| NIH to award funding to support the THIO-101 phase II clinical trial expansion of Maia's ateganosine for non-small-cell lung cancer | Maia Biotechnology Inc. | National Institutes of Health | $2.30 | 9/24/2025 |
| NIH to award funding to evaluate Neucore's targeted exosome platform to deliver an RNA-based therapy against Charcot-Marie-tooth disease type 1a | Neucore Bio Inc. | National Institutes of Health | $0.35 | 9/2/2025 |
| BARDA to award funding to support the development of Orexo's OX-390 for adulterated opioid overdoses | Orexo Inc. | Biomedical Advanced Research and Development Authority | $50.90 | 9/29/2025 |
| Cureator to award RAGE Biotech preclinical funding for the inhaled RAGE therapeutics to treat chronic lung disease | Rage Biotech Pty Ltd. | Cureator | $0.11 | 9/4/2025 |
| Nomic Bio to award Stanford University School of Medicine to support the discovery of therapies against inflammatory bowel disease | Stanford University School of Medicine | Nomic Bio Inc. | Payment unspecified | 9/4/2025 |
| Sunflower Therapeutics Receives NIH SBIR Funding to Develop an Automated, Continuous Cell Disruption Platform for VLP-Based Vaccine Manufacturing | Sunflower Therapeutics PBC | National Institute of Allergy and Infectious Diseases | $0.30 | 9/3/2025 |
| DoD to award Tiziana Life Sciences funding to study Foralumab in traumatic spinal cord injury | Tiziana Life Sciences PLC | US Department of Defense | Payment unspecified | 9/15/2025 |
| Scaleready to award UCLA funding to support invariant natural killer T cell therapy | University of California Los Angeles | Scaleready LLC | $0.15 | 9/9/2025 |
| NIH to award UCLA funding to develop gene therapy against alpha thalassemia | University of California Los Angeles | National Institutes of Health | Payment unspecified | 9/17/2025 |
| Scaleready to award UCSF funding to improve G-Rex based fully-non viral CAR-T cell therapy engineering platform. | University of California San Francisco | Scaleready LLC | $0.20 | 9/9/2025 |
| NCI to award UMMSM funding to develop therapies against diffuse large B-cell lymphoma | University of Miami Miller School of Medicine | National Cancer Institute | $2.40 | 9/2/2025 |
| Breakthrough T1D to award University of Virginia School of Medicine funding to support the phase II trial of CIR-0602K for T1D | University of Virginia | Breakthrough T1D | Payment unspecified | 9/17/2025 |
| The Brain Aneurysm Foundation to award UTHealth Houston funding to study whole genome sequencing for familial IA genes, repurposing a cancer drug and Annexin’s role in SAH pathophysiology | UTHealth Houston McGovern Medicine school | The Brain Aneurysm Foundation | Payment unspecified | 9/10/2025 |
| The V Foundation to award University of Washington School of Medicine funding to support WOKVAC clinical trial against breast cancer | UW School of Medicine | V Foundation for Cancer Research | $0.50 | 9/10/2025 |
| BARDA to award funding to develop Venatorx's oral antibiotic ceftibuten-ledaborbactam etzadroxil for the treatment of complicated urinary tract infections, including pyelonephritis | Venatorx Pharmaceuticals Inc. | Biomedical Advanced Research and Development Authority | $153.00 | 9/25/2025 |
| Anvia Therapeutics to develop Voronoi's VRN-04 for autoimmune diseases | Voronoi | Anvia Therapeutics Inc. | Payment unspecified | 9/22/2025 |
| NIAID to award Weill Cornell Medicine funding to develop a vaccine against HIV | Weill Cornell Medicine | National Institute of Allergy and Infectious Diseases | $20.80 | 9/18/2025 |
| Israel Cancer Research Fund to award to Weizmann Institute of Science funding to support research into antibody-based therapies for lung cancer | Weizmann Institute of Science | Israel Cancer Research Fund Montreal | $0.18 | 9/25/2025 |
| NIAID to award Appili Therapeutics funding to develop fungal vaccine VXV-01 | Appili Therapeutics Inc. | National Institute of Allergy and Infectious Diseases | $40.00 | 10/1/2025 |
| BARDA to award funding to develop Cidara's CD-388 against influenza | Cidara Therapeutics Inc. | Biomedical Advanced Research and Development Authority | $339.00 | 10/2/2025 |
| NIAID to award Cocrystal SBIR Phase I grant to support the development of antiviral candidate against influenza infections | Cocrystal Pharma Inc. | National Institute of Allergy and Infectious Diseases | $0.50 | 10/27/2025 |
| NCI to award Cytoagents funding to accelerate the development of CTO-1681 against multiple myeloma | Cytoagents Inc. | National Cancer Institute | $2.25 | 10/1/2025 |
| AstraZeneca to award Dana-Farber Cancer Institute funding to develop phase III FLAURA2 study of osimertinib plus platinum–pemetrexed combination against NSCLC | Dana Farber Cancer Institute Inc. | Astrazeneca plc | Payment unspecified | 10/17/2025 |
| The DeGregorio Family Foundation to award Dana-Farber Cancer Institute funding to develop druggable targets against gastroesophageal cancer | Dana Farber Cancer Institute Inc. | DeGregorio Family Foundation | $0.30 | 10/17/2025 |
| NIAAA to award DemeRx funding to advance DMX-1001 against Alcohol Use Disorder | Demerx Inc. | National Institute on Alcohol Abuse and Alcoholism | $1.70 | 10/7/2025 |
| NPKUA to award Endure funding to support the development of engineered native bacteria for PKU | Endure Biotherapeutics Inc. | National PKU Alliance Inc. | Payment unspecified | 10/16/2025 |
| NIH to award Evoq funding to develop therapies against celiac disease | Evoq Therapeutics | National Institutes of Health | $2.00 | 10/14/2025 |
| NHLBI to award GeneVentiv Therapeutics funding to support GENV-HEM preclinical toxicology study program against hemophilia A | Geneventiv Therapeutics Inc. | National Heart Lung and Blood Institute | Payment unspecified | 10/7/2025 |
| Government of Quebec to award Glycovax Pharma funding to develop a glycoconjugate vaccine against Pseudomonas aeruginosa infections | Glycovax Pharma Inc. | Quebec government | $0.47 | 10/8/2025 |
| ARPA-H to award Immunovec funding to develop and validate DNA-loaded polymeric nanoparticle platform for autoimmune disease | Immunovec Inc. | The Advanced Research Projects Agency for Health | $40.70 | 10/8/2025 |
| Innovate UK to award Ineos funding to support the development of monoclonal antibodies for antimicrobial resistance | Ineos Oxford Institute for Antimicrobial Research | Innovate UK | Payment unspecified | 10/1/2025 |
| ARPA-H to award Kernal Bio funding to support the clinical development of KR-402 for multiple sclerosis and B-cell malignancies | Kernal Biologics Inc. | The Advanced Research Projects Agency for Health | $48.00 | 10/7/2025 |
| NIH to award funding to support the study to extend Mesoblast's Ryoncil for adults with steroid-refractory acute and chronic graft-versus-host disease | Mesoblast Ltd. | National Institutes of Health | Payment unspecified | 10/19/2025 |
| ARPA-H to award Mount Sinai funding to develop broad spectrum antivirals therapies | Mount Sinai Medical Center Miami | The Advanced Research Projects Agency for Health | $11.80 | 10/21/2025 |
| NIA to award Phase II STTR funding to POP Biotechnologies to develop mosaic immunotherapy against Alzheimer’s disease | POP Biotechnologies Inc. | National Institute on Aging | $2.46 | 10/1/2025 |
| NIH to award funding to develop Pop Bio's therapeutic vaccine against Alzheimer’s disease | POP Biotechnologies Inc. | National Institutes of Health | $2.50 | 10/2/2025 |
| NIAAA to award Psilera funding to support the development of PSIL-006 against alcohol use disorder | Psilera Inc. | National Institute on Alcohol Abuse and Alcoholism | $2.00 | 10/2/2025 |
| NIH to award a Phase II SBIR, Regenerative Medical Solutions grant to advance the prospective cure for diabetes for the next stage of trials | Regenerative Medical Solutions | National Institutes of Health | $1.80 | 10/1/2025 |
| ARPA-H to award Tessera Therapeutics funding to advance in vivo CAR-T therapies | Tessera Therapeutics Inc. | The Advanced Research Projects Agency for Health | $41.30 | 10/8/2025 |
| NCI to award Miller School of Medicine funding to conduct a study of HERV-K retrovirus in GBM resistance | University of Miami Miller School of Medicine | National Cancer Institute | Payment unspecified | 10/2/2025 |
| Gates Foundation to award Vitrivax funding to support the scale-up of ALTA technology | Vitrivax Inc. | Gates Foundation Trust | $9.90 | 10/14/2025 |